Aesica: New Centre to be breath of fresh air for inhalation development

By Dan Stanton

- Last updated on GMT

Related tags Chronic obstructive pulmonary disease

Aesica's new centre to target inhalation development and manufacture
Aesica's new centre to target inhalation development and manufacture
Aesica says its new Lead Technical Centre will be a ‘hotbed of innovation’ providing full inhalation development and manufacturing services.

The centre is set to open at the end of 2014 in Nottingham, UK and will offer the CDMO’s clients formulation development, clinical scale manufacturing and analytical capabilities for inhalation drugs, using spray drying, powder filling and dry powder technologies.

The “Centre will expand and build on the already well-established inhalation expertise at Aesica,” ​Jonathan Faulkes, Business Development Manager at Aesica Formulation Development, told

It will deal with a growth of demand for inhalation products, he continued, from “generics, small life science companies, university groups and large pharmaceutical companies,” ​as they look for “cost-effective delivery of a proof-of-concept clinical trial supplies through to commercial material for their new chemical entity (NCE) or generic / re-purposed product.”

Furthermore, demand is “not all for asthma / chronic obstructive pulmonary disease (COPD),”​ he said, as Aesica is “seeing an increase in medications for other disease areas.”

As for services offered, he added: “Aesica offers a ‘device neutral’ solution; we do not have our own device and therefore we are happy to work with our clients on device technology / unique platforms.”

Growing Brick by BRIC

Faulkes told us Aesica is interested in exploring global opportunities with the BRIC (Brazil, Russia, India and China) countries becoming increasingly important for its clients’ inhalation - as weel as general - business.

This is driven by both economic and environmental factors,”​ he said. “Incidences of COPD are increasingly being linked to smoking and poor air quality.”

Whilst Western countries have begun reducing these factors through clean air initiatives and anti-smoking campaigns, the populations in BRIC nations are becoming wealthier and picking up these vices.

“One could therefore reasonably expect that incidences of COPD will continue to increase in these countries,”​ he said. 

“To meet this expanding market, pharmaceutical companies need to re-examine their product and device portfolios.  Low cost, high efficiency devices will be required for these markets as their governments will no doubt keep a keen eye on health care expenditure.”

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us


View more